Jeffrey R Strich, Ahmed Mishuk, Guoqing Diao, Alexander Lawandi, Willy Li, Cumhur Y Demirkale, Ahmed Babiker, Alex Mancera, Bruce J Swihart, Morgan Walker, Christina Yek, Maniraj Neupane, Nathaniel De Jonge, Sarah Warner, Sameer S Kadri
BACKGROUND: The U.S. antibiotic market failure has threatened future innovation and supply. Understanding when and why clinicians underutilize recently approved gram-negative antibiotics might help prioritize the patient in future antibiotic development and potential market entry rewards. OBJECTIVE: To determine use patterns of recently U.S. Food and Drug Administration (FDA)-approved gram-negative antibiotics (ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, plazomicin, eravacycline, imipenem-relebactam-cilastatin, and cefiderocol) and identify factors associated with their preferential use (over traditional generic agents) in patients with gram-negative infections due to pathogens displaying difficult-to-treat resistance (DTR; that is, resistance to all first-line antibiotics)...
April 19, 2024: Annals of Internal Medicine